BioNTech SE (NASDAQ:BNTX) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Sylke Maas - VP, IR and Business Strategy Ugur Sahin - Co-Founder & CEO Ozlem Tureci - Co-Founder & Chief Medical Officer Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Matthew Harrison - Morgan Stanley Cory Kasimov - JPMorgan Chase & Co. Christopher Zopf - Goldman Sachs Group Akash Tewari - Jefferies Zhiqiang Shu - Berenberg Daina Graybosch - SVB Leerink Operator ...

BioNTech SE (NASDAQ:BNTX) Q4 2021 Earnings Conference Call March 30, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President of Investor Relations & Strategy Ugur Sahin - Chief Executive Officer & Co-Founder Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Sean Marett - Chief Business & Commercial Officer Conference Call Participants Cory Kasimov - JPMorgan Tazeen Ahmad - Bank of America Matthew Harrison - Morgan Stan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exhibit 99.1 BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 1 1 • Fourth quarter and full year revenues of €5.5 billion and €19.0 billion , respectively 2 • Full year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.87 ) • Expect to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose a special cash dividend of €2.00 per share, pending approval at the Annual General Meeting • Approximat ...

Exhibit 99.1 BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 1 1 • Fourth quarter and full year revenues of €5.5 billion and €19.0 billion , respectively 2 • Full year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.87 ) • Expect to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose a special cash dividend of €2.00 per share, pending approval at the Annual General Meeting • Approximat ...

BioNTech SE (NASDAQ:BNTX) JPMorgan 40th Annual Healthcare Conference Call January 11, 2022 9:45 AM ET Company Participants Ugur Sahin - Co-Founder & Chief Executive Officer Jens Holstein - Chief Financial Officer Sean Marett - Chief Business & Commercial Officer Ozlem Tureci - Chief Medical Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Cory Kasimov - JPMorgan Chase & Co. Cory Kasimov Great. Good morning or good afternoon from the 40th Annual JPMorgan Healthcare Conference. My ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...